Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature Medicine

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Gastroenterology

Show all topics

DOI

10.1038/s41591-024-03050-2

License

CC-BY

Other Formats

PDF